Cost-utility analysis of dexamethasone combined with bortezomib and lenalidomide in the treatment of newly diagnosed multiple myeloma
- VernacularTitle:地塞米松联合硼替佐米与来那度胺治疗新诊断多发性骨髓瘤的成本-效用分析
- Author:
Dan HUANG
1
;
Yuanyuan ZHU
2
;
Yue XIAO
3
;
Qiusha LIU
1
;
Sha LIU
1
;
Juan LIU
1
;
Zhengze SHEN
1
Author Information
1. Dept. of Pharmacy，Yongchuan Hospital of Chongqing Medical University，Chongqing 402160，China
2. School of Pharmacy，Chongqing Medical University，Chongqing 400016，China
3. Dept. of Hematology，Yongchuan Hospital of Chongqing Medical University，Chongqing 402160，China
- Publication Type:Journal Article
- Keywords:
bortezomib;
lenalidomide;
dexamethasone
- From:
China Pharmacy
2022;33(16):2001-2005
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To eval uate the cost-util ity of regimen containing bortezomib in the treatment of newly diagnosed multiple myeloma in China. METHODS From the perspective of China ’s health system ，Markov model was constructed based on SWOG S 0777 clinical trial. The simulation time limit was 10 years，and the cycle was set with reference to the treatment cycle. Taking quality adjusted life years （QALYs）as the utility index ，the utility and cost were discounted at a discount rate of 5％；the willingness to pay （WTP）threshold was set to be 3 times of China ’s per capita gross domestic product （GDP）in 2021（242 928 yuan/QALY）. The incremental cost-utility ratio （ICER）of dexamethasone combined with bortezomib and lenalidomide （VRD） versus dexamethasone combined with lenalidomide （RD）were compared with cost-utility analysis. The sensitivity analysis was performed for the uncertainty of the model. RESULTS Results of baseline analysis showed that VRD regimen could obtain 0.65 more QALYs than RD scheme ，but its treatment cost was 135 782.77 yuan more than RD regimen ，ICER was 206 623.35 yuan/ QALY，which was lower than the WTP threshold set in this study ，VRD regimen was cost-effective. Single factor sensitivity analysis showed that the health utility value in progressive free survival had the greatest impact on the results ，the decrease of utility value would make the ICER higher than the WTP threshold ，and VRD regimen would no longer have advantages. Under the WTP threshold of 3 times of China ’s per capita GDP in 2021，the probability of VRD regimen being cost-effective was 86.5％； with the increase of WTP threshold ，the possibility of VRD regimen becoming more cost-effective than RD regimen would increase. CONCLUSIONS Under the WTP threshold of 3 times of China ’s per capita GDP in 2021，compared with RD regimen，VRD regimen is cost-effective in the treatment of newly diagnosed multiple myelo ma in China.
